MXCT
MaxCyte Inc
NASDAQ: MXCT · HEALTHCARE · MEDICAL DEVICES
$0.84
-3.24% today
Updated 2026-05-08
Market cap
$90.34M
P/E ratio
—
P/S ratio
2.74x
EPS (TTM)
$-0.42
Dividend yield
—
52W range
$1 – $2
Volume
0.9M
WallStSmart proprietary scores
30
out of 100
Grade: F
Strong Sell
Investment rating
2.7
Growth
F8.0
Quality
A2.0
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
2.8
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →194 stocks currently score above 75
Price targets
Analyst target
$4.11
+387.02%
12-Month target
—
—
Intrinsic (DCF)
$1.32
Margin of safety
+44.68%
0 Strong Buy5 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ 44.68% below intrinsic value
+ Debt/equity 0.10x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at -135.10%
- Negative free cash flow $-2.92M
- Revenue declining -16.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $44.26M | $41.29M | $38.63M | $33.03M | $33.03M |
| Net income | $-23.57M | $-37.92M | $-41.05M | $-44.63M | $-9.60M |
| EPS | — | — | — | — | $-0.42 |
| Free cash flow | $-33.26M | $-25.39M | $-29.26M | $-36.18M | $-2.92M |
| Profit margin | -53.25% | -91.85% | -106.29% | -135.14% | -135.10% |
Peer comparison
Smart narrative
MaxCyte Inc trades at $0.84. Our Smart Value Score of 30/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 2.78, it sits in the grey zone. TTM revenue stands at $33.03M. with profit margins at -135.10%. Our DCF model estimates intrinsic value at $1.32.
Frequently asked questions
What is MaxCyte Inc's stock price?
MaxCyte Inc (MXCT) trades at $0.84.
Is MaxCyte Inc overvalued?
Smart Value Score 30/100 (Grade F, Strong Sell). DCF value $1.32.
What is the price target of MaxCyte Inc (MXCT)?
The analyst target price is $4.11, representing +387.0% upside from the current price of $0.84.
What is the intrinsic value of MaxCyte Inc (MXCT)?
Based on our DCF model, intrinsic value is $1.32, a +44.7% margin of safety versus $0.84.
What is MaxCyte Inc's revenue?
TTM revenue is $33.03M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
2.78 — grey zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.74x
ROE-23.60%
Beta1.57
50D MA$0.80
200D MA$1.29
Shares out0.11B
Float0.10B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—